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ABSTRACT
Micro-RNAs (miRNAs) are potent regulators of gene
expression and cellular phenotype. Each miRNA
has the potential to target hundreds of transcripts
within the cell thus controlling fundamental cellu-
lar processes such as survival and proliferation.
Here, we exploit this important feature of miRNA
networks to discover vulnerabilities in cancer phe-
notype, and map miRNA-target relationships across
different cancer types. More specifically, we report
the results of a functional genomics screen of 1280
miRNA mimics and inhibitors in eight cancer cell
lines, and its presentation in a sophisticated interac-
tive data portal. This resource represents the most
comprehensive survey of miRNA function in oncol-
ogy, incorporating breast cancer, prostate cancer
and neuroblastoma. A user-friendly web portal cou-
ples this experimental data with multiple tools for
miRNA target prediction, pathway enrichment anal-
ysis and visualization. In addition, the database in-
tegrates publicly available gene expression and per-
turbation data enabling tailored and context-specific
analysis of miRNA function in a particular disease.
As a proof-of-principle, we use the database and its
innovative features to uncover novel determinants of
the neuroblastoma malignant phenotype.
INTRODUCTION
Micro-RNAs (miRNAs) are a class of cellular small non-
coding RNAs that act to regulate protein synthesis through
messenger RNA (mRNA) destabilization and inhibition
of translation (1). Mature miRNAs associate with RNA-
binding proteins into the RNA-induced silencing complex
(RISC) where they exert their effects through hybridization
tomRNA targets.ManymicroRNAs bindmRNAvia com-
plementarity between the 6–8 nt seed of the miRNA with
regions typically in the 3′ untranslated region (UTR) of the
mRNA.
miRNAs control a large diversity of cellular processes,
fromdifferentiation and proliferation to cell death (2–4) and
their deregulation can contribute to human disease aetiol-
ogy. A role for miRNA in cancer is well described (5), and
miRNA are proving valuable as biomarkers and a novel
class of cancer therapeutics (6). Global miRNA expression
decreases with increasing grade in numerous cancers, sug-
gesting a role for some miRNA as tumor-suppressors (7).
The literature contains many reports of miRNA dereg-
ulation and function in many cancer types, but these stud-
ies are typically small scale, lack systematic functional data,
are based on variable selection criteria and are scattered
across a multitude of paradigms and models. As such, there
are many miRNA that remain uncharacterized, and it is
difficult to assess the relative importance of miRNAs to
transformation and tumor-suppression. To address this is-
sue we performed a comprehensive and unbiased reverse ge-
netic screen to identify miRNAs important for cancer sur-
vival in cell line models of three solid cancer types, breast,
prostate and neuroblastoma. We then developed a novel
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web-based data interface to integrate this functional data
with publicly available algorithms formiRNA target predic-
tion, and large-scale datasets of cell-specific gene expression
and gene perturbation experiments. This database stream-
lines the process of identifying the most relevant miRNAs
and their targets for cancer cell survival.
Our screen identifies many well-described tumor-
suppressor miRNAs such as miR-34 and multiple members
of the let-7 family. In addition, we discover numerous other
miRNA with both widespread and disease-restricted roles
in tumor-suppression. Many of these miRNA converge on
overlapping sets of targets, which were over-represented for
members of the FOXO signaling, PI3K-Akt signaling and
stem cell pluripotency pathways.
As a proof of principle, we used our database to search
for novel lethal miRNA and their targets in neuroblastoma,
an aggressive childhood cancer of the sympathetic nervous
system, composed of primitive neural cells with a high
metastatic potential. Only a few oncogenes such as MYCN,
LIN28B or ALK have been directly linked to neuroblas-
toma development and maintenance (8). As the molecular
drivers of neuroblastoma proliferation, differentiation and
survival remain largely unexplored, we used this integrated
miRNA functional database to search for novel determi-
nants of neuroblastoma aetiology. We discovered several
miRNAs with a previously unrecognized role in survival of
neuroblastoma. Furthermore, using our database we un-
cover novel factors necessary for neuroblastoma growth
and survival.
MATERIALS AND METHODS
Cell lines
Breast cancer cell lines (MDA-MB-231, MDA-MB-468,
SK-BR-3; BT474) and prostate cancer cell lines (PC3,
DU145) were obtained from American Type Culture Col-
lection. Neuroblastoma cell lines (KELLY, SHEP) were
received from the Children’s Cancer Institute. All breast
and prostate cancer cell lines were cultivated in Roswell
ParkMemorial Institute (RPMI) media supplemented with
10% Fetal Calf Serum (FCS), HEPES and insulin. KELLY
and SHEP cell lines were grown in 10% FCS/RPMI and
10% FCS/Dulbecco’s modified Eagle’s medium (DMEM),
respectively. MCF10A cells were cultured in DMEM F12
containing 5% horse serum, Epidermal Growth Factor
(EGF), cholera toxin, hydrocortisone and insulin. IMR-
90 cells were grown in 10% FCS/MEM containing sodium
pyruvate and non-essential amino acids.
High-throughput micro-RNA screening
All cell lines were reverse transfected in 384-well plate for-
mat with 25 nM of Dharmacon miRNAmimic or inhibitor
libraries (version 16.0) using a Calliper Sciclone ALH3000
liquid-handling robot according to the conditions listed in
Supplementary Table S1. After 24 h, media was changed
using a BioTek 406 automated plate washer/dispenser, and
6 days posttransfection, cell viability was determined using
the CellTiter-Glo (CTG) luminescent assay (Promega) at
1:2 dilution; luminescence measurements were taken on the
Synergy H4 (BioTek) high-throughput multimode micro-
plate reader. All screens were performed in technical dupli-
cate.
On each library plate we included a large number of posi-
tive and negative technical controls, including non-targeting
ON-TARGETplus siRNA SMARTPool (NT), lipid-only
mock transfection, and mimic and inhibitor non-targeting
controls. For positive controls we selected a panel of siRNA
SMARTpools that when knocked down induce different
levels of cell death including siPLK1, siTOX, siKIF11 or
siCOPB2 (DharmaconRNAi Technologies). Sample values
were normalized to the average of the Nontargeting control
(NT) wells on a per plate basis, and then the duplicate plate
values were averaged. To define screen hits, normalized via-
bility scores were binned in the following manner: CV1 (cell
viability) bin included candidates with viability fold-change
scores of ≥0.8; CV2 bin included candidates with viability
fold-change scores of <0.8 and >0.5; and low cell (LC) bin
was assigned to candidates with viability fold-change scores
of ≤0.5. Only LC candidates were defined as screen hits.
To assess the technical performance of each screen, the
viability values of the positive and negative controls nor-
malized to NT were used to calculate Z′ factor, a quantita-
tive measurement of the dynamic range of an assay (9). The
formula entails:
Z′ = 1 − ((3 (SDof h.v. control+ SDof l.v. controls)) /|h.v. controlmean − l.v. controlmean|)
where, SD indicates standard deviation; h.v. indicates high
value; and l.v. indicates low value.
Z′-values were binned in the following manner: 0.5–1 in-
dicates excellent score; 0.3–0.5 indicates good score; 0–0.3
indicates acceptable score; <0 indicates too much overlap
between the positive and negative controls.
Robust z-score is a normalization strategy that takes into
account all values on a plate and calculates the deviation
from the median of these values. The formula is
Z= (sample value − median (all samples value)) /MAD(all samples value)
where, MAD indicates median absolute deviation.
For alternative inhibitor analysis and hit selection, we set
a threshold of ≤−2.5, corresponding to at least 20% cell
killing.
Validation screen
To confirm the reproducibility of the screen setup, the
lead screen hits in the neuroblastoma cell lines (SHEP and
KELLY) were rescreened under the same conditions as de-
scribed above. The hit validation was performed in another
facility using a Zephyr liquid-handling robot, and the raw
data were analyzed as described above. The viability values
normalized to the NT control from the primary and sec-
ondary screens were then subjected to the correlation anal-
ysis to assess the reproducibility of the assay.
Transfection and cell confluence assays
KELLY and SHEP cells were reverse transfected in 384-
well format using liquid-handling robotics described above
according to the conditions listed in Supplementary Table
S1. For quantitative polymerase chain reaction (qPCR) and
Propidium iodide (PI) uptake experiments, KELLY cells
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were transfected in 6-well plates using 2 l DF1 at 1.4 ×
105 cells/well initial density.
Cell confluence wasmeasured using an IncuCyte ZOOM,
an automated microscopy platform able to take images in
regular intervals over the timespan of the experiment. Im-
ages were taken with a 10× objective at 2 h time intervals.
The software was then trained to recognize live cells and ex-
clude the dead ones on a collection of images, after which
the cell confluence was calculated automatically in all wells
and at all time points. All the graphs display cell confluence
normalized to the NT well at the end point of the experi-
ment.
Propidium iodide (PI) uptake
KELLY cells were transfected in a 6-well plate format as de-
scribed above. Twenty-four hours later media was changed,
and 96 h post-transfection, cells were collected and fixed
with 70% ethanol overnight. The following day, cells were
stained with 1 mg/ml propidium iodide (10 mg/ml final
concentration) and RNAse A for up to 5 h. The cells were
then collected using Canto I, and cell cycle profiles were
constructed using FlowJo.
qPCR
KELLY cells were transfected in a 6-well plate format as de-
scribed above. Twenty-four hours later media was changed,
and 96 h post-transfection, cells were collected for RNA ex-
traction using the miRNeasy isolation kit (Qiagen). RNA
was then subjected to the Reverse transcription (RT) reac-
tion to generate cDNA, which was subsequently quantified
using qPCR and the appropriate Taqman probes. All val-
ues were normalized to two housekeeping genes B2M and
GAPDH. The results were graphed as fold-change com-
pared to the NT control. All experiments were performed
in biological triplicate.
Micro-RNA luciferase-based reporter gene assay
The 3′ UTR sequences of ISL1, HAND1 and RGS16 were
synthesized by Integrated DNA Technologies (IDT) with
the corresponding miR-binding sites either left as wild-type
(WT) sequence (WT 3′ UTR) or mutated to abolish miR-
binding (MUT 3′ UTR). Generated DNA fragments were
then cloned in the psiCHECK-2 vector using NotI and
XhoI restriction enzymes downstream of hRluc gene (re-
nilla luciferase). The psiCHECK-2 contains also hluc+ gene
(firefly luciferase), which enables signal normalization to
correct for variable transfection efficiency between samples.
To perform the luciferase assay, HEK293T cells were
seeded at 2 × 104 cells per well in a 96-well plate, and the
next day, co-transfectedwith 12.5 ng of the reporter plasmid
and 50 nM of the respective miRNA mimic or NT control
using Lipofectamine 3000.MDA-MB-231 cells were seeded
at 2.4 × 104 and co-transfected with 75 ng of the reporter
plasmid and 50 nM of the respective miRNA inhibitor or
NT control using Lipofectamine 3000. Twenty-four hours
later, cells were lysed and subjected to the Dual–Luciferase
Reporter 1000 assay (Promega). Briefly, measurements were
recorded at 0.5 s intervals for a total of 26 s with reagent
injections of 100 l of Luciferase Assay Reagent II (fire-
fly luciferase) at 2 s and 100 l of Stop and Glo Reagent
(renilla luciferase) at 14 s. Renilla luciferase activity was
normalized to the firefly luciferase signal for a readout of
relative miRNA activity. The results were graphed as fold-
change compared to the NT control. All experiments were
performed in biological triplicate.
Small RNA sequencing
For small RNA profiling, the cells were cultured in 6-well
plates for 72 h after which the RNA was extracted using
the miRNeasy kit and sent for sequencing. The analysis of
the FastQ files was performed using Oasis 1.0 sRNA detec-
tion tool (10). Raw count files of filtered miRNAs were then
converted to counts per million.
RESULTS
Experimental design
To systematically identify miRNAs that control the survival
of cancer cells, we performed functional miRNA screens
in breast, prostate and neuroblastoma cancer cells. For
each disease, we selected multiple cell lines, which were
transfected with libraries containing mimics and inhibitors
against 1280 knownmiRNAs amounting to 2560 constructs
in total (Figure 1A).miRNAmimics act asmaturemiRNAs
and are fully functional within a cell while single-stranded
inhibitors efficiently block the activity of endogenous miR-
NAs through competitive binding. To monitor cellular vi-
ability, we used CellTiter-Glo (CTG, Promega), an assay
highly sensitive to changes in cellular adenosine triphos-
phate (ATP) content.
A representative box plot of the entire screen results in the
MDA-MB-231 breast cancer cell line is shown in Figure 1B,
with data from other cell lines shown in Supplementary Fig-
ure S1. In total, over 500 miRNA mimics or inhibitors de-
creased cellular viability >50% in at least one cell line com-
pared to the NT control demonstrating that around 40% of
miRNAs screened are putatively able to regulate survival-
associated pathways in cancer cells (Figure 1C). Differences
in miRNA mimic or inhibitor activities were apparent be-
tween different cancer types and even subtypes of the same
cancer (Figure 1C), supporting the conclusion that the func-
tion of many miRNAs is strongly context dependent (11).
To validate the reproducibility of our screen, we performed
secondary screens in a different laboratory, using KELLY
and SHEP cell lines with selected mimics and inhibitors.
These results demonstrate high reproducibility of our assay
(Figure 1D).
Interestingly, a global overview of the screen results re-
veals profound difference between the effects of miRNA
mimics and inhibitors––only 10 inhibitors reduced viabil-
ity more than 50% in at least one cell line (Figure 1B and C;
Supplementary Figure S2). To understand this observation,
we performed small RNA sequencing in the breast and neu-
roblastoma cell lines, and on average only 180 (∼12%)miR-
NAs showed expression at>100 reads per million in each of
the cell lines, an expression threshold shown to be correlated
with miRNA suppressive activity (12) (Supplementary Fig-
ure S3a). We conclude that the low expression levels of the
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Figure 1. miRNA functional genomics screening in cancer cell lines. (A) The overview of the screen performed across different cancer cell lines. (B) A
summary of the screen results in MDA-MB-231 breast cancer cell line. Y-axis displays CellTiter-Glo (CTG) values normalized to the negative control
(NT) and the X-axis plots miRNA libraries (mimics or inhibitors) as well as the positive death controls (PLK1 and TOX) and additional negative controls
(non-coding inhibitor control (Inhibitor NT), non-coding mimic control (Mimic NT)). (C) An overview of the primary screen hits across different cancer
cell lines. Hits were defined as miR mimics or inhibitors that killed at normalized viability cut-off value ≤0.5. Venn diagram represents an overall number
of hits across three diseases and their intersection, and the table lists the hit breakdown between the mimics and inhibitors. (D) Hit validation in KELLY
and SHEP neuroblastoma cell lines. The graphs plot normalized viability values for selected miRNA mimics or inhibitors in the primary screen against
their values in the secondary validation screen. These were subjected to the correlation analysis, and Pearson correlation coefficient is displayed for each
cell line. The screens were performed in different facilities and on different transfection platforms (see ‘Materials and Methods’ section).
majority of endogenous miRNAs in part explains the low
frequency of inhibitors with activity. We postulated that in-
hibitors would most likely display modest lethal activity, so
we reanalyzed our data using robust z-score statistics and a
less stringent threshold of >20% viability reduction for hit
selection. This led to a higher rate of inhibitor hit detection
(Supplementary Figure S3b). Among these hits, we identi-
fied inhibitors against miR-92a-3p, previously shown to in-
duce potent killing effect in glioma cells (13); miR-125a-5p
inhibitor, which induces apoptosis across different cancer
cells (14); and miR-27a-3p inhibitor, known to decrease vi-
ability of renal cell carcinoma cells (15). Importantly, these
miRNAs were highly expressed in the target cell lines. Be-
cause of the more frequent and stronger lethal effects, how-
ever, we focused on miRNA mimics in all subsequent anal-
yses.
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Database overview
To streamline the search for essential miRNAs and the
mechanisms they use to suppress viability of cancer cells,
we constructed a database that combines screen results with
mRNA and miRNA expression data, published siRNA
screen data, established miRNA target prediction algo-
rithms and a variety of pathway enrichment and visualiza-
tion tools (Figure 2B and Supplementary Figure S4). This
database is available online (http://microrna.garvan.unsw.
edu.au/mtp/search/index).
When searching for potential novel cancer therapy tar-
gets, it is important to consider effects on non-cancerous
tissues and resultant toxicity in patients. We therefore con-
ducted an additional screen in the non-transformed breast
cell line MCF10A as well as the lung fibroblasts IMR-90.
We incorporated these with a published dataset generated in
cardiomyocytes (16) into the database (Figure 2A, ii). These
data can be used to filter formiRNAwith lethality restricted
to cancer cells.
Considering that each miRNA can target hundreds of
genes simultaneously, predicting targets for a singlemiRNA
can be a challenging task. However, our screen uncov-
ered large numbers of miRNAs inducing the same cellu-
lar phenotype and we expect these to have overlapping
targets, allowing the ranking and prioritization of targets
through integrated analysis. A series of filters can be ap-
plied to assist in target identification. First is the choice of
miRNA-target prediction algorithm and thresholds (Figure
2A, iii).We incorporated several widely used computational
algorithms including TargetScan, DIANA and MiRDB.
Importantly, we also included already validated miRNA–
mRNA interactions from high-throughput sequencing of
RNA isolated by crosslinking immunoprecipitation (HITS-
CLIP) and crosslinking, ligation and sequencing of hybrids
(CLASH) experiments stored in StarBase and MirTarBase
databases. A statistical weighting can be applied to any one
of these datasets to suit the research question.
Although high-throughput methods for experimental
target identification greatly improve miRNA target predic-
tion, they are typically performed in one or few cell lines.
Context dependency of miRNA actions, however, limits
their broader use and requires additional cell- or tissue-
specific filters. We therefore incorporated into the database
RNA sequencing data for both coding and non-coding tar-
gets in all cell lines allowing for the option to remove tar-
gets that are expressed below a specified threshold (Figure
2A, iii). Finally, to increase the confidence of finding targets
that mediate miRNA tumor-suppressor activity, we incor-
porated the results of large siRNAessential screens from the
DPSC-cancer database (Figure 2A, iii). This database pro-
vides data on the requirement for cellular survival of over 16
000 genes in cancer cells and can be used to determine the
requirement for each predicted miRNA target in cell sur-
vival.
After selecting preferred filtering options, an analysis
reaches the ‘Target analysis’ page (Supplementary Figure
S4). A summary is provided of howmanymiRNAs and tar-
gets remain after filtering and the number of each biotype of
predicted targets (e.g. protein-coding, lincRNA, snoRNA).
The data tab displays a table with all the targets and their
unique score, a metric that takes into account the number
of miRNAs targeting a specific gene as well as the number
of databases providing evidence for that relationship. The
‘Heatmap’ tab gives an immediate overview of the relation-
ship between miRNAs and targets for a specified number of
targets. Finally, the ‘Expression’ tab provides unsupervized
clustering of all the cell lines in the database according to
target expression levels.
The final filtered set of miRNAs and targets can be fur-
ther analyzed and visualized using custom internal and ex-
ternal methods, including pathway enrichment tools. The
database also provides summary heatmaps to visualize
miRNAs, targets and pathways. Alternatively, a selected
target list can be analyzed using Reactome API or three
external tools Enrichr, DAVID and String DB. Finally,
we included a Biodalliance genome browser track (http:
//www.biodalliance.org/), which automatically displays the
selected target and their location in the genome. For further
details about site construction, data origin and database
structure see SupplementaryData.Also, to fully explore op-
tions within the database, follow the page-specific tours and
help buttons.
Data summary across cancer types
We next used the database and its inbuilt features to take
a closer look at lethal miRNA mimics in each of the an-
alyzed cancer types. As noted previously, differences in
miRNA mimic activities were evident not only between
diseases (Figure 1C) but also subtypes or cell lines of the
same cancer type (Figure 3A). Breast cancer cell lines,
for instance, displayed widely different profiles with triple-
negative cell linesMDA-MB-231 andMDA-MB-468 show-
ing significantly higher number of hits and a different set of
lethal miRNA compared with ER+ and HER+ cell lines
BT474 and SK-BR-3, respectively. Prostate cancer cell lines
PC3 and DU145, which are both castrate-resistant and an-
drogen signaling independent showed less divergence, and
hundreds of mimics acted as potent tumor-suppressors in
each of the cell lines. Similarly, neuroblastoma cell lines
KELLY (MYCN amplified) and SHEP (MYCN WT) dis-
played comparably high number of lethal miRNA mimic
hits. These results reflect at least in part the heterogeneous
biology of different tumor types and subtypes.
To get a broad overview of each of the cancer types’ bi-
ology, we searched for miR candidates that were lethal (vi-
ability cut-off ≤0.5) when overexpressed in cell lines rep-
resenting a particular cancer type. The database displays a
list of all miRNA mimics and inhibitors acting at a spec-
ified cut-off and groups them according to their member-
ship of sequence-related miRNA families. Figure 3B dis-
plays part of this data and shows miR families that were
enriched for lethal miR candidates in a particular disease.
Most of the candidates were hits in more than one cancer
type (white bars), but in each of the diseases there were miR
family members potently killing only the cells of the partic-
ular type (Figure 3B, black bars). For instance, members
of the miR-515, miR-506 and miR-154 families were active
across different diseases, but other members showed speci-
ficity for a particular cancer type, suggesting the existing of
unique targets between members of these families.
Downloaded from https://academic.oup.com/nar/article-abstract/45/22/12657/4634316
by University Library user
on 15 June 2018
12662 Nucleic Acids Research, 2017, Vol. 45, No. 22
Figure 2. miRNA function database structure and metrics. (A, i) miR Selection: mining of the screening data gives a list of miRNAs with a lethal effect
in one or more cancer cell lines, or a custom list can be used. (A, ii) miR filtering: there is an option of excluding miRNAs that affect normal cells, for
example cardiomyocytes and normal breast cells. (A, iii) Target filtering: the miRNAs are further subjected to five different target prediction algorithms
and the targets are ranked according to the strength of predictions and the number of miRNAs that target them. The targets are prioritized based on their
expression in the relevant cell line as well as their impact on the survival of the same cell line (siRNA screens). (A, iv) Interaction analysis: the final list
of targets can be further analyzed using internal and external gene enrichment tools. (B) A list of all external data incorporated in the miRNA function
database. Detailed summary can be found in the Supplementary Methods.
We next used the database to look at the predicted tar-
gets of the most enriched miRNA families specific for each
of the cancer types. The targets were ranked according to
their database score and the top 100 targets were analysed
for the enrichment of Kyoto Encyclopaedia of Genes and
Genomes (KEGG) pathways (Figure 3C).
In breast cancer cell lines, the only significantly en-
riched pathways were FoxO and TGF-, and the predicted
targets mediating these pathways included among others
TGFBR2, THBS1, BMPR2, SP1 as well as several apopto-
sis regulators such as BCL2L11, DDX3X andMCL1 (Sup-
plementary figures S5a and S6). The miRNAs predicted to
regulate targets in these pathways included among others
miR-181b-5p and miR-181d-5p (miR-181 family) as well
as miR-99b-5p (miR-10 family), which have been shown to
operate within the TGF- signaling axis in normal breast
cells and breast cancer cells (17,18). Additional miR fam-
ilies with the predicted activity in the pathway were miR-
25 (miR-25-3p andmiR-92a-3p) andmiR-515 family (miR-
525-3p, miR-524-3p and miR-520f-3p) as well as the addi-
tional member of the miR-10 family (miR-125a-5p) (Sup-
plementary Figure S5a).
In neuroblastoma cells, where numerous disease-specific
lethal miRNAs clustered into miRNA families, the top en-
riched KEGG pathways included some of the same path-
ways appearing in the breast cancer cell line (Figure 3C
and Supplementary Figure S5c), however the targets driv-
ing enrichment of these pathways were different and over-
represented for those known to be neuroblastoma specific
or important in this disease. Enriched pathways include
the insulin-like growth factor pathway, which regulates pro-
liferation and survival in many pediatric cancers includ-
ing neuroblastoma (19) (Supplementary Figure S6c). Foxo
pathway and Foxo transcription factors, in addition, reg-
ulate differentiation of neuroblastoma cells (20). This tar-
get signature was largely driven by the let-7 family of miR-
NAs, established tumor-suppressors in neuroblastoma ae-
tiology (21), but other miRNAs families such as miR-506
(miR-507, miR-508-3p, miR-511), miR-27 (miR-27a-3p,
miR-27b-5p) and miR-15 (miR-15b-5p, miR-195-5p) were
strongly predicted to regulate these targets (Supplementary
Figures S5c and 6c). Interestingly, melanoma and glioma
KEGG pathways were also enriched, perhaps reflecting
their shared neural (glioma) and neural crest (melanoma)
origin with neuroblastoma.
Prostate cancer cell lines displayed the least disease-
specific lethal miRNAs, but we observed the miR-500 fam-
ily to be enriched among these hits with three members po-
tently killing up to 80% of cells (miR-501-5p, miR-500a-5p
and miR-500b-5p). Interestingly, none of the miR-500 can-
didates showed activity in normal MCF10A and cardiac
cells. This family has not been described before in the con-
text of prostate disease.
Although the enrichment analysis of predicted miRNA
targets did not showany significantly enrichedKEGGpath-
ways after adjusting for multiple testing (Figure 3C), path-
ways related to fatty acid metabolism showed enrichment
trends driven by gene targets such as ACADSB, ACSL6,
SCP2 and PEX2 (Supplementary Figures S5b and 6b).
Fatty acid metabolism is a dominant bioenergetics pathway
in prostate cancer cells and increased lipid synthesis is as-
sociated with cell growth, survival and drug resistance (22).
Based on our data and database predictions, miR-500 fam-
ily members and their targets may be novel candidates to be
investigated in prostate cancer.
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Figure 3. Data summary across different diseases. (A) Venn diagrams depict number of hits and their intersection across different cell types in each of the
diseases. (B) For each cancer type, the graphs listing the most enriched miR families (three or more members) among the screen hits (at a viability cut-off
≤0.5) are presented. The white portion of the bars shows the number of lethal miR family members irrespective of the cancer type (general) and the black
portion shows the members that were disease specific (disease-specific). The graphs are adapted from the database (enriched families with two members
were omitted for better legibility). (C) The disease-specific miR family members were subjected to target prediction analyzed for the enrichment of KEGG
pathways. The enrichment was regarded as significant at False Discovery Rate (FDR) ≤0.05.
Identification of lethal microRNA and their targets in neu-
roblastoma
To validate that our dataset and database can identify pre-
viously known biology as well as generate new biologi-
cal insights, we focused on miRNAs acting potently as
tumor-suppressors in neuroblastoma. For this purpose, we
queried screen results in the KELLY cell line, which mod-
els poor-prognosis MYCN-amplified disease and selected
only miRNAs that killed at a very stringent normalized
viability of ≤0.3 relative to controls. The resulting list of
184miRNAmimics contained 13miRNA already shown to
act as tumor-suppressors in neuroblastoma and to supress
MYCN expression (23), including ninemembers of the let-7
family in addition to miR-19b-1-5p, miR-34a-3p, miR-101-
3p and miR-202-3p (Figure 4A and Supplementary Figure
S7a). Interestingly, let-7 family members were only lethal in
neuroblastoma cell lines. Next, we looked at the most com-
monly shared predicted targets between these miRNAs and
filtered them according to their expression levels in KELLY
cells (RPKM>1 for protein coding genes). Remarkably, nu-
merous genes were predicted to be targeted by a majority of
these miRNA, suggesting the existence of a highly intercon-
nected network of miRNA and their targets (Supplemen-
tary Figure S7b). For instance, out of the top 100 predicted
targets, 7 are known to be major cancer-related genes and
are targeted by at least 70% of these miRNAs.
These targets were enriched for genes with well-described
roles in oncology (KEGG enrichment tab; data not shown)
including DICER1, DUSP1, TGFBR1 and EZH2 (Fig-
ure 4B). Importantly, MYCN was one of the top tar-
gets, agreeing with previously published data. In addition,
several other bona fide oncogenes in neuroblastoma ap-
peared among the top targets. LIN28B is a well-known
target of the let-7 family of miRNAs, and has been re-
cently shown to play a major role in neuroblastoma devel-
opment through a feedback loop involving let-7 miRNAs
and MYCN (24). IGF2BP1, another top candidate in our
list, is highly expressed in neuroblastoma, frequently associ-
ated with MYCN amplification and shown to strongly pro-
moteMYCN expression levels (25). To check whether these
genes are trulymiRNA targets in our system, we chose three
representative miRNA, let-7b-5p, miR-101-3p and miR-
202-3p, transfected the KELLY cell line with miRNAmim-
ics and examined the expression of MYCN and LIN28B
by reverse transcriptase PCR. Both MYCN and LIN28B
mRNA levels were significantly reduced as predicted by our
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Figure 4. Validation of the screening and data analysis pipeline. (A) A heatmap showing the lethal effect (normalized viability values) of the miRNAs
known to affect neuroblastoma survival through targeting MYCN. Red color signifies strong lethal effect and white color no effect on cell survival. (B)
The list of top 20 targets most commonly shared between these miRNAs as computed by our database. The targets were ranked according to the strength
of predictions and filtered based on their expression levels in KELLYs (RPKM > 1). (C) KELLY cells were transfected with let-7b-5p, miR-101-3, miR-
202-3p or NT, and changes in mRNA levels of MYCN and LIN28B were assessed using qPCR. B2M was used as a housekeeping gene. The graph plots
gene expression (dCt expression) relative to B2M and is representative of three independent experiments. The significance was determined using one-way
ANOVA with Dunnett’s multiple comparisons test (n = 3, *P-value ≤ 0.05).
database (Figure 4C). Therefore our database effectively
identifies previously validated lethal miRNA and their tar-
gets ab initio.
Identification of novel micro-RNA targets essential for neu-
roblastoma survival
Experimental techniques for miRNA target identification
unequivocally demonstrate that individual miRNAs can in-
teract with many mRNAs within the cell. We therefore
searched for additional targets of these validated lethal
miRNA that might play a significant and specific role in
neuroblastoma aetiology. The database-predicted targets
of MYCN-targeting miRNAs (Supplementary Figure S7)
were significantly enriched for two KEGG pathways, ‘miR-
NAs in cancer’ and ‘signaling pathways regulating pluripo-
tency of stem cells’ (Supplementary Figure S8a). When
we clustered these predicted targets according to their ex-
pression level across the panel of eight cell lines (‘Expres-
sion’ tab), we noticed a number of targets in addition to
MYCN and LIN28B with high expression in the KELLY
cell line but very low expression in breast and prostate can-
cer (Supplementary Figure S8b; first 50 targets displayed).
We chose four such factors (HAND1, RGS16, RBFOX2
andACVR2B) that exhibited high expression levels in other
neuroblastoma cell lines (data derived fromOncomine) and
were not previously implicated in neuroblastoma biology
for further analysis. We again transfected KELLY cells with
miR-101-3p, miR-202-3p and let-7b-5p mimics and mea-
sured the mRNA levels of HAND1, RGS16, RBFOX2
and ACVR2B. In agreement with the predictions, miRNA
overexpression downregulated the majority of targets (Fig-
ure 5A). Mining of high-throughput CLASH and HITS-
CLIP experiments revealed multiple lines of experimental
evidence for direct binding between these miRNA–mRNA
pairs (26,27). We confirmed these results using luciferase-
based reporter assays for HAND1 and RGS16 (Figure 5B).
Transfection of let-7b-5p significantly reduced the luciferase
signal when co-transfected with a vector carrying WT 3′
UTR of both HAND1 and RGS16. This effect was com-
pletely abolished in the presence of RGS16 3′ UTR with
a mutated let-7b-5p-binding site, and only partially res-
cued in the presence of the mutated HAND1 3′ UTR, sug-
gesting additional binding sites for this miRNA. To deter-
mine whether endogenous Let-7b can target HAND1 and
RGS16, we selected the MDA-MB-231 cell line, which ex-
presses high levels of endogenous let-7b-5p miRNA and
co-transfected it with let-7b-5p inhibitor and WT or mu-
tant HAND1 and RGS16 reporter vectors. In both cases,
the presence of let-7b-5p inhibitor increased the luciferase
signal of the WT let-7b-5p reporter but not the mutant re-
porter (Figure 5B). These data validate our discovery ap-
proach by demonstrating that Let-7b can directly target
HAND1 and RGS16 through binding to specific sites in the
3′ UTR.
We next sought to investigate whether these factors have
an impact on neuroblastoma survival. Knockdown of all
four of the novel factors reduced either cell confluence
and/or ATP content, similar to knockdown of MYCN or
LIN28B (Figure 5C). In particular, RGS16 and RBFOX2
siRNAs led to a dramatic decrease of KELLY cell viability
in all biological replicates and assay types, suggesting that
these previously unrecognized factors play a fundamental
role in neuroblastoma cell viability. These data suggest that
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Figure 5. Novel let-7 targets regulate the survival of neuroblastoma cancer cells. (A) KELLY cells were transfected with let-7b-5p, miR-101-3, miR-202-3p
or NT, and changes in mRNA levels of HAND1, RGS16, ACVR2B and RBFOX2 were assessed using qPCR. B2M was used as a housekeeping gene. The
graph plots gene expression (dCt expression) relative to B2M and is representative of three independent experiments. The significance was determined using
one-way ANOVA with Dunnett’s multiple comparisons test (n = 3, *P-value ≤ 0.05). (B) HEK293T and MDA-MB-231 cells were co-transfected with
NT or let-7b-5p mimic or inhibitor, and HAND1 or RGS16 reporter plasmid encoding either WT or mutated 3′ UTR. Twenty-four hours later, the cell
lysates were prepared and subjected to dual luciferase assay to measure both firefly (control) and renilla luciferase (experimental signal). The graph plots
fold-change relative to NT control and is representative of three independent experiments. The significance was determined using two-way ANOVA with
Sidak’s multiple comparisons test (n = 3, *P-value ≤ 0.05). (C) KELLY cells were transfected with siRNAs against MYCN, LIN28B, HAND1, RGS16,
ACVR2B, RBFOX2 or NT control in 384-well format. The images of the wells were taken every 2 h for 3 days using IncuCyte ZOOM system. Cell viability
was determined using CellTiter-Glo luminescent assay. Both cell confluence and cell viability were plotted as values normalized to the NT control, and each
graph is a representative of three independent experiments. The significance was determined using one-way ANOVA with Dunnett’s multiple comparisons
test (*P-value ≤ 0.05).
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miRNAs can be used as a novel perturbation to discover
protein-coding genes important in disease.
Identification of novel microRNAs with a role in neuroblas-
toma aetiology
We next mined our functional screening data to uncover
previously unrecognizedmiRNAs important for neuroblas-
toma biology. We queried the database for other miRNA
families that effectively kill KELLY or SHEP cells at the
original cut-off of normalized viability ≤0.5. The most en-
riched family besides let-7 miRNAs was the miR-515 fam-
ily with 14 members exhibiting a potent tumor-suppressor
effect, which has not been previously described in neurob-
lastoma (Figure 3B and Figure 6A). Seven of these were
selectively lethal to neuroblastoma, particularly MYCN-
amplified KELLY cells (Figure 6A). To investigate the un-
derlying mechanism of their lethality, we applied target pre-
diction algorithms to the 14 miR-515 family members and
obtained a list of ranked high-confidence targets clustered
based on their expression in our panel of cancer cell lines
(Supplementary Figure S9a). Many of the targets were ex-
pressed across all cell lines, but several were specifically ex-
pressed in KELLY cells. One such mRNA was the tran-
scription factor SOX11 (database score 0.29; targeted by
5/14 miRNAs). While a role for SOX11 in neuroblastoma
is not described, it is essential for the development of sym-
pathetic neural ganglia, a likely cell of origin for some neu-
roblastoma (28). Another top candidate predicted to be tar-
geted by 5/14 miRNAs (database score 0.36) was ISL-1,
a LIM homeobox transcription factor highly expressed in
primary neuroblastoma tumors and cell lines compared to
other tumor types (Supplementary Figure S9b). In agree-
ment with the database prediction, transfection with miR-
517a-5p mimic downregulated Isl1 levels in KELLY cells
(Figure 6B). In addition, mining of HITS-CLIP data (29)
demonstrates direct binding ofmiR-517a-5p to Isl1mRNA.
We confirmed this finding by performing a reporter assay
for ISL1. Transfection of miR-517a significantly reduced
the luciferase signal when co-transfected with a vector car-
rying WT 3′ UTR and this affect was completely abol-
ished in the presence of a vector carrying the 3′ UTR with
a mutated miR-517a-binding site (Figure 6C). Finally, we
wanted to determine whether ISL1 plays a role in neurob-
lastoma survival as this has not been previously shown. In-
deed, transfection with siRNA against ISL1 markedly re-
duced the confluence of KELLY cell cultures (Figure 6D
and Supplementary Figure S9c). ISL1 knockdown also re-
duced proliferation based on a reduced S-phase fraction
in DNA histograms (Figure 6E). In addition, ISL1 knock-
down led to a dramatic change in cellular morphology into
tightly packed clusters of rounded cells (Supplementary
Figure S9c) suggesting changes in differentiation. We mea-
sured two differentiation markers of the neuronal lineage
previously reported to increase in KELLY cells upon differ-
entiation, NTRK1 and NEFL. Knockdown of ISL1 repro-
ducibly increased the levels ofNTRK1, a neurotrophic tyro-
sine kinase receptor known to mediate neuroblastoma dif-
ferentiation in differentmodels (30,31), suggesting a role for
ISL1 in neuroblastoma differentiation (Figure 6F). Taken
together, our functional screen and miRNA target analysis
uncovered a previously unrecognized role for the miR-515
family and its novel targets in neuroblastoma.
DISCUSSION
miRNA target hundreds of transcripts within a cell and reg-
ulate the most fundamental cellular processes including tu-
morigensis and cancer cell survival. The large majority of
studies rely on miRNA expression changes to identify the
most relevant miRNAs in this context, which does not nec-
essarily identify functionally important miRNAs. One so-
lution to this problem is to use high-throughput functional
screening approaches, and in the last several years, there
have been a number of reports that applied this method-
ology to systematically explore miRNA function in human
cancers (32–35). All these studies, however, focused on one
specific context or cancer type (and typically only one cell
line model) and analysed a limited subset of miRNA, typ-
ically <400. They all have limited integration with other
datasets such as target predictions, miRNA and mRNA ex-
pression and siRNA screens. Here, we greatly expand these
efforts by exploring the function of 1280 miRNA across
eight cell lines representing three cancer types. In addition,
we provide an easy-to-use environment to interrogate this
data and perform downstream analyses. The result is the
identification of hundreds of miRNAs with previously un-
known roles in cancer proliferation and survival and the dis-
covery of novel miRNA targets required in disease. Two im-
portant caveats of our study are worth noting: the first is
that proliferation in 2D cell culture was used as our screen-
ing endpoint, and we did not measure the impact of miR-
NAs on other phenotypes important to cancer, such as self-
renewal or invasion. These endpoints may be incorporated
into the database through subsequent studies. Second, due
to the nature of the screen, increases in proliferation or sur-
vival followingmiRNAmimic or inhibitor transfectionmay
not have been detected.
One of the difficulties in exploring miRNA biology
is identification of direct targets. Experimental methods
for verifying direct interactions are laborious and time-
consuming while computational algorithms generate nu-
merous false positives and negatives. An important feature
of our database is the integration of multiple orthogonal
datasets to allow users to parse the list of predicted tar-
gets and rank them according to the strength of predictions
and additional information available for that particular tar-
get. We based these filtering steps on several assumptions.
First, mRNAs containing canonical seed matches––which
are therefore more likely to be predicted by multiple com-
putational algorithms––are also more likely to be genuine
mRNA targets. Indeed, recent reports demonstrate more
significant repression by miRNAs of targets containing 8
and 7 mer seed sites compared to the ones containing only
6 mer matches or non-canonical binding sites (36). Pre-
dicted targets in our database are initially assigned a score
based on how many algorithms recognized them as targets.
Importantly, the users are able to complement this by giv-
ing more weight to experimentally derived targets. A sec-
ond important assumption is that miRNAs exerting simi-
lar lethal effects will function through overlapping targets.
Indeed, miRNA co-targeting has been found to be ubiqui-
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Figure 6. Novel determinants of neuroblastoma cell survival. (A) A heatmap showing the lethal effect (normalized cell viability) of the miR-515 family
members in all screened cancer cell lines. ‘Count’ on the histogram represents the frequency of miRNAs showing a particular lethal effect. Seven family
members are hits (normalized viability cut-off ≤0.5) only in KELLY cells. Red color signifies strong lethal effect and white color no effect on cell survival.
(B) KELLY cells were transfected with miR-517a-3p or NT control, and changes in mRNA levels of ISL1 were assessed using qPCR. B2M was used
as a housekeeping gene. The graph plots gene expression (dCt expression) relative to B2M and is representative of three independent experiments. The
significance was determined using a t-test (n = 3, *P-value ≤ 0.05). (C) HEK293T cells were co-transfected with NT or miR-517a and reporter plasmid
encoding eitherWT ormutated ISL1 3′ UTR. Twenty-four hours later, the cells lysates were prepared and subjected to dual luciferase assay tomeasure both
firefly (control) and renilla luciferase (experimental signal). The graph plots fold-change relative to NT control and is representative of three independent
experiments. The significance was determined using two-way ANOVA with Sidak’s multiple comparisons test (n = 3, *P-value ≤ 0.05). (D) KELLY cells
were transfected with a SMARTpool siRNA against ISL1 or NT control in a 384-well format. The images of the wells were taken every 2 h over 3 days using
the IncuCyte ZOOM system. Cell confluence was plotted as values normalized to the NT control and is representative of three independent experiments.
The significance was determined using a t-test (*P-value ≤ 0.05). (E) KELLY cells were transfected with a SMARTpool siRNA against ISL1 or NT
control, and 96 h later, cells were fixed and stained with PI. Cell cycle profiles were determined using Canto I and FlowJo for data analysis. Histograms are
representative of three independent experiments. (F) KELLY cells were transfected with a SMARTpool siRNA against ISL1 or NT control, and changes
in mRNA levels of differentiation markers NEFL and NTRK1 were assessed using qPCR. B2M was used as a housekeeping gene. The graph plots gene
expression levels relative to B2M and is representative of three independent experiments. The significance was determined using two-way ANOVA with
Sidak’s multiple comparisons test (*P-value ≤ 0.05).
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tous amongmiRNAs, which frequently function together to
regulate target-gene expression (37). For a given set of miR-
NAs, our database can be used to search for the most com-
monly shared targets, which are assigned a higher database
score and therefore rank higher then the less connected
targets. The list of targets can be additionally customized
by using gene expression data to eliminate low abundance
mRNA.This is an important feature of the database consid-
ering the context-dependency ofmiRNA regulatory activity
(38). It should be noted that a limitation of our database is
that targets repressed via non-seed based mechanisms will
be poorly represented in predictions.
Previous findings demonstrated that malignant tissues
display widespread downregulation of miRNAs related to
a less differentiated phenotype (5), suggesting that miRNA
on the whole are tumor-suppressive. Consistent with this,
more than 40% of miRNA mimics were active in at least
one cell line, and in most cell lines we observed hundreds
of miRNA mimics with a lethal effect. One could argue,
however, that such dramatic effects result from an overex-
pression ofmiRNAmimics upon transfection, causing non-
physiological effects that would not be otherwise present
in these tissues. We note two important points of discus-
sion here. First, transfection with candidate miRNA mim-
ics at markedly lower concentrations recapitulated the po-
tent lethal effects observed at higher concentrations (data
not shown). Furthermore, it has been previously shown
that upon transfection a large portion of miRNA mimic
molecules ends up in vesicles and is therefore not functional
while the functional fraction, associated with the RISC,
is comparable to the most abundant endogenous miRNAs
(39).
Second, only a fraction of lethal miRNAs from our
screens are likely to function as tumor-suppressors under
physiological conditions, and this screen data and associ-
ated analytical tools should be seen as a starting point for
further analysis of candidatemiRNAnetworks arising from
this perturbation screen. Regardless of their endogenous
role, miRNAs with potent activity in this screen may be
important candidate therapeutics for miRNA replacement
therapy.
An important observation from our analyses is the di-
verse and specific activity ofmiRNA familymembers across
disease models. While family members would be predicted
to act similarly due to their sequence homology, some
members of the miR-515 family, for instance, showed ac-
tivity in all three diseases, while other members had ac-
tivity restricted to breast cancer or neuroblastoma mod-
els. For these miRNAs, the predicted targets are different,
and are enriched for adhesion signaling molecules and the
RAS-MAPK/PI3K-Akt signaling axis, respectively (data
not shown and Figure 3C). Although these predictions and
their importance for the disease would have to be experi-
mentally validated, this example illustrates a complex rela-
tionship between miRNAs and their targets, and the under-
lying effect of the local transcriptional landscape.
We used neuroblastoma to test the value of our miRNA
functional database in identifying not just newmiRNA, but
also novel protein-coding targets controlling cancer aetiol-
ogy. We identified numerous miRNA previously associated
with neuroblastoma to also be lethal in our screen, thus
validating our screening approach. This included the let-7
family of miRNAs, which interestingly we find to be lethal
specifically in MYCN-amplified neuroblastoma (KELLY
cell line) and not in breast or prostate cancer cell lines (data
not shown). We identified novel let-7 targets that might be
involved in neuroblastoma initiation or maintenance in ad-
dition to the well-characterized MYCN and LIN28B onco-
genes. RGS16 belongs to a family of G-protein signaling
regulators with somemembers already implicated in human
cancer (40). Furthermore, RBFOX2 acts as a splicing reg-
ulator involved in stem cell differentiation as well as reg-
ulation of cancer-specific splicing signatures (41,42). More
detailed investigation of the role for these two genes in neu-
roblastoma cell differentiation, proliferation and survival in
long-term assays is warranted.
We also identified several members of the miR-515 seed
family with a novel role in neuroblastoma. Interestingly, five
of these miRNA target ISL-1, a LIM homeobox transcrip-
tional coactivator, which is expressed by cardiac neural crest
derivatives and is important for cardiac progenitor survival
during development (43,44). ISL1 is expressed by pancre-
atic well-differentiated neuroendocrine neoplasms, but in
extrapancreatic tumors, it appears to be restricted to neu-
roblastomas (45). Profiling of 48 stage four neuroblastoma
tumors revealed ISL1 to be a reliable marker of minimal
residual disease (46). For the first time, we show here a func-
tional role for ISL1 in neuroblastoma cell survival most
likely through regulating the switch between cellular prolif-
eration and differentiation. Further experiments are needed
to pinpoint ISL1 transcriptional targets and clarify its rela-
tionship with other known determinants of neuroblastoma
proliferation and differentiation.
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